Navigation Links
Crestor Patent Invalidity Evidence Uncovered By Article One Partners Community
Date:7/1/2009

AstraZeneca Patent Shown to be Invalid Based on New Prior Art; JSA Technologies Patent Study Yields Strong Invalidity Evidence

NEW YORK, July 1 /PRNewswire/ -- Article One Partners, LLC has discovered new prior art impacting the validity of AstraZeneca's Crestor U.S. drug patent, in closing out another round of Patent Studies. The Article One community uncovered premier validity evidence which can show the Crestor patent to be invalid, as verified by independent outside counsel, Darby & Darby, and an independent expert. CRESTOR(R) (rosuvastatin calcium) is a prescription drug for treating high cholesterol. The discovery of this patent invalidity evidence can impact the industry litigation to market generic rosuvastatin drugs. The prior art (further detailed below) was provided by an Article One community Advisor with the username Columbo, who will receive a monetary award.

JSA Technologies Study Uncovers Two Key References

In addition to the Crestor Study, Article One's JSA Technologies Study for U.S. Patent No. 6,963,857 uncovered a broad range of prior art references, including two references that each separately can show the patent to be invalid under the strongest level of invalidity evidence, called anticipation. The JSA patent involves transferring funds from a second account to a first account with the accounts on separate networks and servers--such as transferring funds onto university student ID cards. Two Advisors, with usernames Ramesh and Patented, identified the evidence and will share the monetary reward.

Article One already has begun to license the proprietary collection, with law firm Davis Wright Tremaine, LLP first to license. The JSA Study uncovered new dramatic invalidating prior art that extensive traditional prior art searches didn't produce. With so many Article One Advisors using different approaches, a wide variety of highest quality references were found--providi
'/>"/>

SOURCE Article One Partners, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. CRESTOR(R) Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated Cholesterol
2. Analyst Available to Comment on New JUPITER Study That Shows AstraZenecas Crestor Significantly Reduces CV Risk
3. CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study
4. As a Result of the Jupiter Trial, 65 Percent of Surveyed MCO Pharmacy Directors Will Reimburse Crestor for Patients with Elevated hsCRP
5. Video: CRESTOR(R) Reduced Risk of Blood Clots in the Veins
6. Patent Reform Legislation Threatens Americas Leadership in Medical Technology Innovation
7. Spectranetics to Appeal Decision in Patent Litigation
8. Patent Expiries of Proscar and Flomax/Harnal Will Cause a Significant Decline in Near-Term Sales of Benign Prostatic Hyperplasia Drugs
9. Actavis Confirms its Patent Challenge of Kings Avinza(R)
10. PartsSource Awarded US Patent for PartsFinder(TM) Application
11. Barr Confirms Patent Challenge of UROXATRAL(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... from Sub-Saharan Africa, Latin America and Caribbean islands ... new research from St. Michael,s Hospital. , The ... of Obstetrics and Gynaecology , assessed the differences ... native-born women in six high-immigration countries Australia ... Valencia) and the United States (California, New Jersey ...
(Date:4/23/2014)... director at the National Institute of Arthritis and Musculoskeletal ... recipient of the Ross Prize in Molecular Medicine, conferred ... Medicine . The award will be given on June ... Manhattan, followed by scientific presentations by Dr. O,Shea and ... Institutes of Health. , The award, which includes a ...
(Date:4/23/2014)... report that rats exposed to high-energy particles, simulating conditions ... show lapses in attention and slower reaction times, even ... ranges. , The cognitive impairments which affected a ... appear to be linked to protein changes in ... to hold true in humans, suggest it may be ...
(Date:4/23/2014)... N.Y. A novel compound that targets an important ... of cocaine addiction behaviors, including relapse behavior, a University ... provides strong evidence that this may be a novel ... effective medications exist., The UB research was published as ... week. , In the study, the compound, RO5263397, severely ...
(Date:4/23/2014)... new computer program could help doctors predict which patients ... treatment. , The program, which assesses brain scans ... airport security and passport control, has been developed by ... study funded by the Wellcome Trust, which used the ... . , Stroke affects over 15 million people ...
Breaking Medicine News(10 mins):Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3
... ... every year, 35 to 50 million Americans become infected with the flu (influenza). On average, ... Plano, TX is taking steps to combat these preventable deaths by offering free flu shots ... Plano, TX (Vocus) September 12, ...
... , , , ... important safety notice to its more than 750,000 subscribers of its ... wearing a "pendant" style help button. The service is used primarily ... at risk of falls. By pressing a "help button" worn on ...
... of Public Health has been awarded $18.4 million by ... U.S. Department of Defense to establish an Extremity Trauma ... the coordinating center for the Consortium that includes a ... with several major military treatment centers and the U.S. ...
... ... on the Failed War on Drugs , ... Las Vegas, NV (PRWEB) September 11, 2009 -- PAINWeek® 2009, the national conference ... drug reform in the United States as keynote speaker former Assistant US Attorney Jennifer Bolen, ...
... help predict who,s susceptible to the disease, study says , ... to a higher risk of Alzheimer,s disease seems to affect ... thought, new research suggests. , The brains of people in ... -- which boosts the risk of Alzheimer,s but doesn,t guarantee ...
... , NEW YORK, Sept. 11 Duane Reade Holdings ... that, as the Local Presenting Sponsor of the 2009 Komen New ... its foundation, The Duane Reade Charitable Foundation, have raised $330,000 to ... to find a cure. This marks the third year that Duane ...
Cached Medicine News:Health News:H1N1 frenzy may allow regular flu to be more deadly than ever 2Health News:Lifeline Issues Safety Notice to Subscribers 2Health News:JHSPH to lead extremity trauma clinical research consortium 2Health News:JHSPH to lead extremity trauma clinical research consortium 3Health News:Healthcare Legal Issues Take the Stage at PAINWeek 2009 2Health News:Healthcare Legal Issues Take the Stage at PAINWeek 2009 3Health News:Alzheimer's Gene Affects Brains of Young Adults 2Health News:New Yorkers Help Duane Reade Increase Support of the 19th Annual Komen New York City Race For The Cure(R) 2Health News:New Yorkers Help Duane Reade Increase Support of the 19th Annual Komen New York City Race For The Cure(R) 3
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ... the fourth quarter of 2013 on Monday, February 3, 2014. ... after the close of trading. (Logo: ... to discuss the operating highlights and financial results for the ...
(Date:1/14/2014)... 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company ... Progressive Home Medical Equipment, Inc. ("Progressive") of Clarion, ... the acquisition were not disclosed. Progressive is ... wide range of sleep, mobility, and respiratory products to customers ...
(Date:1/14/2014)... PLYMOUTH, Minn. , Jan. 14, 2014   NuAire , a ... come to agreement with Hitachi Koki of ... centrifuges in North America . NuAire will utilize ... and Canada to offer assistance ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... Be Presented --, SAN FRANCISCO, April 24, 2007 /PRNewswire-FirstCall/ ... Phase,2 efficacy study of Dimebon(TM) in Alzheimer's disease will ... at the American,Academy of Neurology's 59th Annual Meeting in ... The presentation will include new,data from both the mild ...
... WIRE)--Apr 24, 2007 - Ceragenix Pharmaceuticals,Inc. (OTCBB:CGXP) ... study comparing EpiCeram's(TM) efficacy to,that of Cutivate(R) ... of moderate-to-severe atopic dermatitis (AD)., The study, ... of 113,pediatric patients, with 59 patients receiving ...
Cached Medicine Technology:Medivation Announces First U.S. Presentation of Data From Dimebon,Phase 2 Alzheimer's Disease Trial at American Academy of Neurology,Annual Meeting 2Medivation Announces First U.S. Presentation of Data From Dimebon,Phase 2 Alzheimer's Disease Trial at American Academy of Neurology,Annual Meeting 3Ceragenix Announces Results from Phase IV Study of EpiCeram Meet,All Primary and Secondary Endpoints 2Ceragenix Announces Results from Phase IV Study of EpiCeram Meet,All Primary and Secondary Endpoints 3Ceragenix Announces Results from Phase IV Study of EpiCeram Meet,All Primary and Secondary Endpoints 4Ceragenix Announces Results from Phase IV Study of EpiCeram Meet,All Primary and Secondary Endpoints 5Ceragenix Announces Results from Phase IV Study of EpiCeram Meet,All Primary and Secondary Endpoints 6
... of Hemoglobin S in patient samples. Each ... and 20l of anticoagulated whole blood or ... test kit contains two bottles of phosphate ... and two vials of Sodium Hydrosulfite reagent ...
... CD-Chex Plus BC is an assayed control ... systems. CD-Chex Plus BC determines the accuracy ... in the process of immunophenotyping, including red ... subsets of leukocytes include: T lymphocytes, B ...
Streck-T-Pack is specially designed for use on Coulter® Counter T Series instruments. Each convenient pack includes diluent, lysing agent and enzymatic cleanser. The shelf life is 18 months from ...
... CD-Chex CD34 is a ... leukocytes which can be used ... when evaluating CD34 positive cells. ... ISHAGE and ProCOUNT gating strategies. ...
Medicine Products: